Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 2/20 | 0.39 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 8/20 | 0.32 |
| ▸ | JAK3 | P52333 | 8/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678385 | 0.76 | PKM (0.53) | MAP3K7TAB1PKMJAK2 | |
| SCHEMBL31070084 | 0.76 | PKM (0.53) | MAP3K7TAB1PKMJAK2 | |
| SCHEMBL2600511 | 0.71 | ROCK2 (0.37) | JAK2JAK3 | |
| SCHEMBL9923368 | 0.69 | CAMKK2 (0.39) | MAP3K7TAB1JAK2JAK3 | |
| SCHEMBL25290288 | 0.67 | MAP3K7 (0.51) | MAP3K7TAB1PKMJAK2JAK3 | |
| SCHEMBL30566019 | 0.67 | MAP3K7 (0.51) | MAP3K7TAB1PKMJAK2JAK3 | |
| SCHEMBL20758384 | 0.65 | AXL (0.41) | MAP3K7TAB1JAK2JAK3MAP4K1 | |
| SCHEMBL9923471 | 0.64 | CAMKK2 (0.38) | MAP3K7TAB1JAK2JAK3MAP4K1 | |
| SCHEMBL23204597 | 0.64 | MAP2K1 (0.38) | MAP3K7TAB1PKMJAK2JAK3 | |
| SCHEMBL7943876 | 0.63 | MEN1 (0.37) | CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020033955-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |